Healthcare Systems' Liquidity Challenge

Healthcare systems are facing rising operating pressure, thinner margins, and a harder question about how to manage liquidity across the balance sheet as capital needs become more uncertain. Liquidity is an issue, and an enterprise risk management approach that factors in organizational risks when setting investment strategy can help.

Seeking Alpha • 9 hours ago

Which iShares Healthcare ETF Is the Better Buy: Diversified IXJ or Biotech-Focused IBB?

iShares Global Healthcare ETF provides lower-cost exposure to the broader medical sector than iShares Biotechnology ETF. iShares Biotechnology ETF has delivered higher 1-year total returns but with significantly greater price volatility.

The Motley Fool • Jul 23, 2026

Playing The Biotech Breakout With Insiders

Biotech stocks are consolidating after a breakout, with bullish insider Wall Street sentiment. AbCellera Biologics and Alpha Cognition stand out for insider buying, revenue growth, and high Seeking Alpha Quant Ratings. ABCL's Phase 2 efficacy readout for ABCL635 in Q3 and ACOG's Zunveyl sales ramp are key catalysts. Both have substantial upside per analyst targets.

Seeking Alpha • Jul 23, 2026

Kospi jumps 6% as Asia's battered semiconductor trade rebounds

Asian stocks rallied on Wednesday as investors returned to semiconductor shares after a bruising sell-off, taking their cue from a Wall Street rebound even as Brent crude pushed further above $91 a barrel. MSCI's Asia-Pacific gauge outside Japan gained 1.2%, while South Korea's Kospi surged more than 6% and Japan's Nikkei 225 climbed 1.9%.

Invezz • Jul 22, 2026

Buying Biotech's Policy Discount With XBI And IBB: Most 'Feared' Nation Policy, Less-Than-Feared Damage

I initiate Buy ratings on SPDR S&P Biotech ETF and iShares Biotechnology ETF for 2026–2027, favoring XBI for higher upside. Biotech's rally reflects improving fundamentals: robust M&A, positive clinical data, improved financing, and more quantifiable policy risk, not indiscriminate multiple expansion. MFN drug-pricing risk is narrower than feared, with emerging policies fragmented by payer, product, geography, and voluntary manufacturer participation.

Seeking Alpha • Jul 21, 2026

AI Bubble Risks Make Dividend Stocks Attractive Again

I identify dividend stocks and REITs that could protect investors from AI bubble risks, geopolitics, and inflation while generating attractive income. My "ALLKA Dividend Rating" model separates quality dividend opportunities from yield traps by analyzing dividend sustainability, growth prospects, and valuation. The article explores three dividend strategies, "High-Yield Defensive," "Balanced Income," and "Pure Growth," designed for goals ranging from high yield to dividend growth.

Seeking Alpha • Jul 18, 2026

Biotech ETFs: How Do FBT and IBB Match Up on Cost, Structure, and Performance?

First Trust NYSE Arca Biotechnology Index Fund offers a more concentrated portfolio with only 30 holdings compared to the 248 positions in iShares Biotechnology ETF iShares Biotechnology ETF is the larger and more established fund, having launched in 2001 and managing $9.6 billion in assets under management First Trust NYSE Arca Biotechnology Index Fund has achieved a higher total return over both one-year and five-year horizons

The Motley Fool • Jul 12, 2026

IHE vs. IBB: Which iShares Healthcare ETF Is the Better Buy?

The iShares U.S. Pharmaceuticals ETF (IHE) offers a lower expense ratio and a significantly higher dividend yield than the iShares Biotechnology ETF (IBB). IBB offers broader diversification, with 248 holdings compared to just 56 for IHE.

The Motley Fool • Jul 10, 2026

U.S. Biotechs Are Keeping More Secrets to Beat Copycats in China

Western biotechs get a new playbook with tighter controls to stay ahead of China's “fast follower” pharmaceutical pipeline.

WSJ • Jul 10, 2026

3 Healthcare ETFs to Own in a Choppy Stock Market

Healthcare stocks are attractive in a choppy market. These funds, focusing on the broader sector, drugmakers, and biotechs, are worth a look.

Barrons • Jul 6, 2026